Balchem Corporation (NASDAQ: BCPC) is a company engaged in the development, manufacturing, distribution, and marketing of specialty performance ingredients and products across various markets. The company provides scientifically proven health benefits and enhances taste in products ranging from infant formulas to performance shakes and functional foods. Balchem operates through three primary business segments, focusing on human and animal nutrition, as well as specialty products for various industries.
-
Human Nutrition & Health - Provides human-grade choline nutrients, mineral amino acid chelated products, specialty vitamin K2, and methylsulfonylmethane (MSM). Serves the food and beverage industry with customized ingredient systems and microencapsulation solutions for various applications.
-
Animal Nutrition & Health - Manufactures and supplies products to various animal health markets, catering to the nutritional needs of ruminants, swine, poultry, and companion animals.
-
Specialty Products - Specializes in the re-packaging and worldwide distribution of select sterilants and fumigants, particularly for medical device sterilization and spice and nutmeat fumigation. Includes the Plant Nutrition business unit, providing chelated minerals under the trade name Metalosate® to the agricultural market.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Theodore L. Harris ExecutiveBoard | Chairman, President, and Chief Executive Officer | Independent Director at Pentair plc | Theodore L. Harris is the Chairman, President, and Chief Executive Officer of Balchem Corporation since January 2017. He has a robust background with previous senior leadership roles at Ashland Inc. and currently serves as an Independent Director at Pentair plc. | View Report → |
C. Martin Bengtsson Executive | Executive Vice President and Chief Financial Officer | C. Martin Bengtsson has served as Executive Vice President and Chief Financial Officer at Balchem Corporation since February 2019. He also holds the additional role of General Manager of Animal Nutrition and Health since March 2024. Previously, he was CFO for Honeywell’s Performance Materials & Technologies segment and started his career at Deloitte. | ||
Frederic Boned Executive | Senior Vice President and General Manager, Human Nutrition and Health | Frederic Boned is Senior Vice President and General Manager, Human Nutrition and Health at BCPC since November 2022, previously serving in key leadership roles at DSM between September 2018 and November 2022. | ||
Hatsuki Miyata Executive | Executive Vice President, Chief Legal Officer, and Secretary | Hatsuki Miyata is the Executive Vice President, Chief Legal Officer, and Secretary at BCPC since February 2025. Previously, she served as Executive Vice President, General Counsel, and Secretary starting in July 2022. | ||
Job L. van Gunsteren Executive | Senior Vice President and General Manager, Specialty Products | Job L. van Gunsteren has been the Senior Vice President and General Manager, Specialty Products at Balchem Corporation since September 2022 and previously served as Vice President and General Manager, Specialty Products from August 2019 to September 2022 and Director for Animal Nutrition and Health – EMEA from 2013 to 2019. | ||
M. Brent Tignor Executive | Senior Vice President and Chief Human Resources Officer | M. Brent Tignor is the Senior Vice President and Chief Human Resources Officer at Balchem Corporation since September 2022, and previously served as Vice President and Chief Human Resources Officer from February 2022 to September 2022 as well as Vice President, Human Resources from 2016 to February 2022. | ||
Martin L. Reid Executive | Senior Vice President and Chief Supply Chain Officer | Martin L. Reid is Senior Vice President and Chief Supply Chain Officer at Balchem Corporation since September 2022. He previously served as Vice President and Chief Supply Chain Officer from January 2021 to September 2022 and as Chief Supply Chain Officer at Godiva Chocolate from May 2019 to December 2020. | ||
Michael R. Sestrick Executive | Senior Vice President and Chief Technology Officer | Michael R. Sestrick, Ph.D. has been serving as Senior Vice President and Chief Technology Officer at Balchem Corporation since September 2022, previously serving as Vice President and Chief Technology Officer from April 2017 to September 2022. | ||
William A. Backus Executive | Vice President and Chief Accounting Officer | William A. Backus has served as Vice President and Chief Accounting Officer at Balchem Corporation since October 2017 and previously served as interim Chief Financial Officer from October 2018 to February 2019. He announced his intent to retire on March 31, 2026. | ||
Daniel Knutson Board | Independent Director | Daniel Knutson has served as an Independent Director at BCPC since 2018 and is a Class 3 Director with his term expiring in 2026. Previously, he held executive roles at Land O'Lakes, including serving as Executive Vice President and CFO from 2000 to 2017. | ||
David Fischer Board | Class 3 Director | Director at Ingredion Incorporated (NYSE) | David Fischer is a Class 3 Director at BCPC, serving as an Independent Director since 2010 with a term expiring in 2026. He serves on the Executive, Compensation, and Governance committees and brings extensive expertise in global manufacturing and M&A to the board. | |
Kathleen Fish Board | Class 2 Director | Director at Origin Materials, Inc. | Kathleen Fish is a Class 2 Director at BCPC, serving as an Independent Director since 2022 with her term expiring in 2027 and acting as Chair of the Governance Committee since February 2023. Previously, she held executive roles at P&G as Chief Technology Officer from 2014 to 2017 and Chief Research, Development and Innovation Officer from 2017 to 2020. | |
Matthew Wineinger Board | Class 1 Director and Lead Director | President and Chief Executive Officer at United Sugars Producers and Refiners Cooperative | Matthew Wineinger is a Class 1 Director and Lead Director at BCPC, serving as an independent director since 2015 and chairing the Executive and Compensation Committees since February 2023. Previously, he has served as President and Chief Executive Officer at United Sugars Producers and Refiners Cooperative since June 2015 and held leadership roles at Tate & Lyle from 2008 to 2014. | |
Monica Vicente Board | Class 1 Director | Senior Vice President and Chief Financial Officer at Fresh Del Monte Produce Inc. | Monica Vicente is a Class 1 Director at Balchem Corporation, serving as an Independent Director since 2023 with her term set to expire in 2025 and pending re-election for the 2028 annual meeting of shareholders. Prior to BCPC, she has been the Senior Vice President and Chief Financial Officer at Fresh Del Monte Produce Inc. since April 2022, after serving 19 years as Vice President, Corporate Finance. | |
Olivier Rigaud Board | Independent Director | CEO and Chair of the Board of Management for Corbion N.V.; Executive Committee Member at Corbion N.V. | Olivier Rigaud is an Independent Director at BCPC since September 6, 2023. He brings over 30 years of industry experience having served as CEO and Chair of the Board of Management for Corbion N.V. since August 2019 and previously held the role of CEO at Naturex. |
- With tariffs potentially impacting approximately $20 million in raw material costs, could you detail the specific steps and timeline for shifting sources and raising prices, and explain how sustainable these measures are in a competitive market?
- Considering the uncertainties in global trade and the risk of recessionary conditions, which market segments do you view as most vulnerable, and what detailed contingency plans have you put in place to mitigate these risks?
- In light of your anti-dumping case currently under EU review, what are the specific financial and strategic impacts you anticipate if the ruling does not go in your favor, particularly regarding export margins?
- Given your commentary on the translational and transactional FX impacts—with a noted change from a 105 to 115 rate—could you provide more insight into how these fluctuations are expected to affect your revenue and earnings on a quarterly basis?
- Your capital allocation strategy entails balancing debt reduction, M&A opportunities, and share repurchases; could you elaborate on the quantitative criteria you use to prioritize these options amidst current market uncertainties?
Research analysts who have asked questions during BALCHEM earnings calls.
Raghuram Selvaraju
H.C. Wainwright & Co.
4 questions for BCPC
Daniel Harriman
Sidoti & Company, LLC
3 questions for BCPC
Bob Labick
CJS Securities
2 questions for BCPC
Anthony Polak
Aegis Capital Corporation
1 question for BCPC
Kyle May
Stifel
1 question for BCPC
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Bergstrom Nutrition | 2022 | Acquired by Balchem’s subsidiary, Albion Laboratories, via a stock purchase agreement with total payments of $70,892 (net $68,967) and a contingent earn‐out liability up to $16 million; the acquisition of its high‐quality MSM manufacturing capability builds synergies within Balchem’s Human Nutrition & Health and Animal Nutrition & Health segments and was structured to capture scientific and technical advantages. |
Kappa Bioscience AS | 2022 | Acquired for a total consideration of approximately $327.3 million (including a contingent payment of about $24.7 million and an EV/EBITDA multiple of 18x) to integrate its patented vitamin K2 (K2VITAL®) technologies into Balchem’s portfolio, thereby enhancing its scientific expertise, geographic reach in Europe, and market leadership in human nutrition. |
Recent press releases and 8-K filings for BCPC.
Balchem Corporation reported strong financial performance for Q3 2025, continuing its double-digit sales and earnings growth. The company also demonstrated strong cash flows supporting a healthy balance sheet, with all three business segments delivering solid growth. Growth is further strengthened by "better for you" food and nutrition market trends, benefiting Balchem's portfolio of specialty nutrients and functional solutions. Additionally, Balchem has surpassed its 2030 GHG emissions reduction goal, reducing Scope 1 and 2 emissions by 32%.
| Metric | Q3 2025 | YTD 2025 |
|---|---|---|
| Sales ($USD Millions) | $267.6 | $773.5 |
| Adj. EBITDA ($USD Millions) | $71.4 | $207.0 |
| Adj. Net Earnings ($USD Millions) | $44.0 | $125.6 |
| Adj. EPS ($USD) | $1.35 | $3.84 |
- Balchem reported record quarterly consolidated sales of $268 million, an 11.5% increase year-over-year, marking its 25th consecutive quarter of year-over-year adjusted EBITDA growth.
- The company achieved record quarterly adjusted EBITDA of $71 million, up 11%, and record adjusted diluted EPS of $1.35, an increase of 19.5% compared to the prior year.
- Human Nutrition and Health segment sales grew 14.3% to $174 million, and the Specialty Products segment grew 7.5%, with Plant Nutrition growing 13%.
- Balchem is investing in a new microencapsulation plant with twice the capacity, expected to be completed and producing by early 2027, to support the 26% growth in its encapsulates business.
- The company's net debt decreased to $89 million, resulting in a leverage ratio of 0.3, and maintains a positive outlook for the remainder of the year.
- Balchem reported record Q3 2025 consolidated revenue of $268 million, an 11.5% increase year-over-year, marking the 25th consecutive quarter of year-over-year adjusted EBITDA growth.
- The company achieved record adjusted EBITDA of $71 million (up 11% year-over-year) and record adjusted diluted EPS of $1.35 (up 19.5% year-over-year).
- All three segments contributed to growth, with the Human Nutrition and Health segment's sales increasing 14.3% to $174 million.
- Construction of a new microencapsulation manufacturing facility in Orange County is expected to be completed in early 2027 and operational by mid-2027, doubling capacity for this high-growth product line.
- The European Union's preliminary anti-dumping duties on China-origin choline chloride are anticipated to receive final approval by the end of 2025, with a five-year term.
- Balchem Corporation reported record net sales of $267.6 million for the third quarter of 2025, an 11.5% increase compared to the prior year quarter.
- The company achieved GAAP net earnings of $40.3 million, up 19.1%, and record adjusted EBITDA of $71.4 million, up 11.0% from the prior year quarter.
- GAAP earnings per share were $1.24 and adjusted earnings per share were $1.35 for Q3 2025, compared to $1.03 and $1.13 respectively in the prior year quarter.
- All three reporting segments, Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, experienced sales and earnings growth. Balchem is also moving forward with a new microencapsulation manufacturing facility in Orange County, NY, which will more than double capacity , and made net repayments of $36.0 million on its revolving debt, bringing net debt to $88.9 million with a 0.3 times leverage ratio.
- Balchem Corporation reported record net sales of $267.6 million for the third quarter ended September 30, 2025, an 11.5% increase compared to the prior year quarter.
- GAAP net earnings for Q3 2025 were $40.3 million, a 19.1% increase from the prior year, with GAAP earnings per share of $1.24 and record adjusted earnings per share of $1.35.
- The company achieved record adjusted EBITDA of $71.4 million, up 11.0% from the prior year quarter, and generated free cash flow of $50.7 million.
- All three reporting segments experienced sales and earnings from operations growth.
- Balchem received approvals to proceed with a new state-of-the-art food ingredient and nutraceutical microencapsulation manufacturing facility in Orange County, NY, which will more than double capacity.
- Balchem Corp reported record Q2 2025 consolidated sales of $255 million, an increase of 9.1% year-over-year, and record adjusted diluted EPS of $1.27.
- The company plans to build a new $36 million microencapsulation manufacturing facility in New York, which is expected to more than double its capacity and support continued double-digit growth.
- Management maintains a positive outlook for the second half of 2025, citing healthy demand across most end markets.
- Provisional anti-dumping duties of 95% to 120% on Chinese choline by the European Commission are anticipated to positively impact the Animal Nutrition and Health segment.